Sun Pharma Presents Robust Long-Term UNLOXCYT Data at ESMO 2026
Sun Pharmaceutical Industries Ltd · Press Release · 23 Oct 2026, 11:31 pm
Sun Pharma Presents Robust Long-Term UNLOXCYT Data at ESMO 2026 Sun Pharma announced updated long-term pivotal trial data for UNLOXCYT (cosibelimab-ipdl) in advanced cutaneous squamous cell carcinoma at ESMO on 24th Oct'26. In locally advanced CSCC, the drug achieved a 53.1% objective response rate (ORR) with a 34.4% complete response (CR) and a median progression-free survival (PFS) of 37.3 months. Metastatic CSCC cohorts recorded ORRs of 44.4% to 51.3% (CRs of 16.7%–20.6%). Estimated 24-month response durability ranged between 69% and 82%, alongside a favorable safety profile showing 2.9% Grade 3 immune-related adverse events.
Original exchange filing (PDF)
More announcements from Sun Pharmaceutical Industries Ltd
- Intimation of Schedule of Analyst/Institutional Investor Meeting · 05 Nov 2026
- Q2FY27 Earnings Call Transcript · 05 Nov 2026
- Clarification regarding news report relating to the Company''s Assam facility · 03 Nov 2026
- The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on November 2, 2026, with reference to news appeared in https://www.thehindu.com/ dated October 30, 2026 quoting .... · 02 Nov 2026
- Completion and results of postal ballot dated 01 October 2026 · 01 Nov 2026
- Q2FY27- Investor Call Audio Recording · 31 Oct 2026
- Board Meeting Outcome - Conclusion · 30 Oct 2026
- Unaudited Financial Results for the quarter and half year ended 30 September 2026 · 30 Oct 2026
